Trial Profile
A phase II study of imatinib mesylate plus hydroxyurea in the treatment of patients with recurrent/progressive meningioma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2013
Price :
$35
*
At a glance
- Drugs Hydroxycarbamide (Primary) ; Imatinib (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- 11 Oct 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov. (NCT00611234).
- 11 Oct 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov. (NCT00611234).
- 11 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00611234).